NCT03404752View on ClinicalTrials.gov

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

PHASE3UnknownINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

December 31, 2018

Conditions

Breast Cancer

Interventions

DRUG

Peg-Filgrastim

Trial Locations (1)

Unknown

RECRUITING

COIBA, Buenos Aires

Sponsors

Lead Sponsor

Gema Biotech S.A.

All Listed Sponsors

collaborator

QUID Quality in Drugs and Devices Latin American Consulting SRL

OTHER

lead

Gema Biotech S.A.

INDUSTRY